"Increasing our majority stake in Hyperscale Data aligns with our strategic vision to expand our footprint in the data technology sector,” said Milton C. Ault, III, Chief Executive Officer of Ault & ...
The FDA has accepted for filing and priority review Sentynl Therapeutics’ CUTX-101 NDA for the treatment of Menkes disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback